Comparison between Corona Remedies IPO and Ravi Infrabuild Projects IPO.
Corona Remedies IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Ravi Infrabuild Projects IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Corona Remedies IPO is up to ₹655.37 Cr whereas the issue size of the Ravi Infrabuild Projects IPO is up to ₹1,100.00 Cr. The final issue price of Corona Remedies IPO is ₹1,062.00 per share and of Ravi Infrabuild Projects IPO is .
| Corona Remedies IPO | Ravi Infrabuild Projects IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹1,008.00 per share | |
| Issue Price (Upper) | ₹1,062.00 per share | |
| Issue Price (Final) | ₹1,062.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹54.00 per share | |
| Market Lot Size | 14 shares | |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹1,100.00 Cr |
| OFS Issue Size | 61,74,051 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹655.37 Cr | up to ₹0.00 Cr |
| Issue Size Total | 61,74,051 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹655.37 Cr | up to ₹1,100.00 Cr |
Corona Remedies IPO opens on Dec 08, 2025, while Ravi Infrabuild Projects IPO opens on . The closing date of Corona Remedies IPO and Ravi Infrabuild Projects IPO is Dec 10, 2025, and , respectively.
| Corona Remedies IPO | Ravi Infrabuild Projects IPO | |
|---|---|---|
| Anchor Bid Date | Dec 05, 2025 | |
| Issue Open | Dec 08, 2025 | |
| Issue Close | Dec 10, 2025 | |
| Basis Of Allotment (Tentative) | Dec 11, 2025 | |
| Initiation of Refunds (Tentative) | Dec 12, 2025 | |
| Credit of Share (Tentative) | Dec 12, 2025 | |
| Listing date (Tentative) | Dec 15, 2025 | |
| Anchor Lockin End date 1 | Jan 09, 2026 | |
| Anchor Lockin End date 2 | Mar 10, 2026 |
Corona Remedies IPO P/E ratio is 43.47, as compared to Ravi Infrabuild Projects IPO P/E ratio of .
| Corona Remedies IPO | Ravi Infrabuild Projects IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 72.5 | 100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 43.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹6495.20 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 27.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 41.32% | 17.87% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.10 | 1.84 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹24.43 | ₹16.63 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 24.65% | 28.10% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Corona Remedies IPO Retail Individual Investors (RII) are offered 21,40,606 shares while in Ravi Infrabuild Projects IPO retail investors are offered 21,40,606 shares. Qualified Institutional Buyers (QIB) are offered 12,23,203 shares in Corona Remedies IPO and in Ravi Infrabuild Projects IPO.
| Corona Remedies IPO | Ravi Infrabuild Projects IPO | |
|---|---|---|
| Anchor Investor Reservation | 18,34,804 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 12,23,203 shares | |
| NII | 9,17,403 shares | |
| RII | 21,40,606 shares | |
| Employee | 58,035 shares | |
| Others | ||
| Total | 61,74,051 shares |
Corona Remedies IPO subscribed 144.54x in total, whereas Ravi Infrabuild Projects IPO subscribed .
| Corona Remedies IPO | Ravi Infrabuild Projects IPO | |
|---|---|---|
| QIB (times) | 293.80x | |
| NII (times) | 220.18x | |
| Big NII (times) | 246.67x | |
| Small NII (times) | 167.20x | |
| RII (times) | 30.39x | |
| Employee (times) | 15.56x | |
| Other (times) | ||
| Total (times) | 144.54x |
